An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock): incorporating a systematic review, meta-analysis and value of information analysis

TY - JOUR

T1 - An evaluation of the feasibility, cost and value of information of a multicentre randomised controlled trial of intravenous immunoglobulin for sepsis (severe sepsis and septic shock)

T2 - incorporating a systematic review, meta-analysis and value of information analysis

AU - Soares, M O

AU - Welton, N J

AU - Harrison, D A

AU - Peura, P

AU - Shankar- Hari, M

AU - Harvey, S E

AU - Madan, J J

AU - Ades, A E

AU - Palmer, S J

AU - Rowan, K M

PY - 2012/2

Y1 - 2012/2

N2 - Sepsis is a syndrome characterised by a systemic inflammatory response to infection that leads to rapid acute organ failure and potentially rapid decline to death. Intravenous immunoglobulin (IVIG), a blood product derived from human donor blood, has been proposed as an adjuvant therapy for sepsis.

AB - Sepsis is a syndrome characterised by a systemic inflammatory response to infection that leads to rapid acute organ failure and potentially rapid decline to death. Intravenous immunoglobulin (IVIG), a blood product derived from human donor blood, has been proposed as an adjuvant therapy for sepsis.

UR - http://www.scopus.com/inward/record.url?scp=84857879859&partnerID=8YFLogxK

U2 - 10.3310/hta16070

DO - 10.3310/hta16070

M3 - Article

C2 - 22361003

SN - 1366-5278

VL - 16

SP - 1

EP - 186

JO - Health technology assessment

JF - Health technology assessment

IS - 7

ER -